Experimental Antibody-Drug Conjugate Shrinks Brain Metastasis in Rare Salivary Gland Cancer
A case report describes a durable 54.5 percent shrinkage of a dural-based brain metastasis in a patient with HER2-negative salivary ...
A case report describes a durable 54.5 percent shrinkage of a dural-based brain metastasis in a patient with HER2-negative salivary ...
The phase II DETECT IVb trial confirms eribulin's efficacy and safety in HER2-negative metastatic breast cancer and shows that early ...
A 12-year Japanese database study of 16,573 patients shows first-line nivolumab plus chemotherapy rapidly displaced cisplatin-based regimens in HER2-negative advanced ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine